Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
Add more filters










Database
Language
Publication year range
1.
Immunotherapy ; 13(14): 1193-1204, 2021 10.
Article in English | MEDLINE | ID: mdl-34328018

ABSTRACT

Aim: Clinical efficacy of sublingual immunotherapy for grass pollen-induced allergic rhinitis (AR) needs to translate into patient benefit. Patients & methods: Patients received Oralair (Stallergenes, Antony, France) in real-life medical practice. Patient-relevant treatment benefits were measured with the AR-specific Patient Benefit Index. Subgroups were analyzed regarding distinct patient characteristics. Results: Data of 883 patients (children, adolescents, and adults) were analyzed. The highest-ranked patient needs referred to having less AR symptoms, being able to go outdoors, and being free in the choice of leisure activities. Most patients (89.2-94.6%) attained at least minimally relevant benefit. All subgroups reported relevant benefits, with significantly higher scores in some subgroups. Conclusion: Treatment with Oralair was associated with considerable patient-relevant benefit in all age groups.


Subject(s)
Rhinitis, Allergic, Seasonal/therapy , Sublingual Immunotherapy/methods , Treatment Outcome , Adolescent , Adult , Aged , Allergens/administration & dosage , Antigens, Plant/administration & dosage , Child , Child, Preschool , Female , Humans , Longitudinal Studies , Male , Middle Aged , Patient Reported Outcome Measures , Plant Extracts/administration & dosage , Poaceae , Young Adult
2.
Adv Ther ; 37(6): 2932-2945, 2020 06.
Article in English | MEDLINE | ID: mdl-32342352

ABSTRACT

INTRODUCTION: Sublingual immunotherapy (SLIT) with birch pollen extract has been shown to be an efficacious treatment of allergic rhinitis (AR). An as-yet unanswered question is whether and how clinical benefit translates into patient benefit, i.e. what benefit patients derive from this treatment. METHODS: This 1-year, open, prospective, multicenter, non-interventional study conducted in 75 German centers measured patient-relevant benefit of birch pollen SLIT (Staloral® Birch) using the questionnaire "Patient Benefit Index for Allergic Rhinitis (PBI-AR)". At treatment onset, patients rated the importance of 25 treatment needs; after the first birch pollen season on treatment, goal achievement was evaluated. A preference-weighted benefit index was calculated and its association with gender, asthma, allergy status, and severity of AR symptoms was determined. RESULTS: Mean age of the 291 adult patients was 38.8 years; 58.4% were female. The most important treatment goals were to "be able to stay outdoors without symptoms" (87.3% quite or very important), "no longer have a runny or stuffed-up nose" (86.9%), and "be able to breathe through your nose more freely" (86.9%). The treatment goals with the highest benefit ratings (referring to those patients to whom the respective goal applied) were to "have confidence in the therapy" (60.5% has helped "quite" or "very much"), "have an easily applicable treatment" (55.6%), and "be able to breathe through my nose more freely" (51.7%). The average PBI-AR global score was 2.19 (SD 1.04) (0-4; with 4 indicating maximum benefit). No significant differences in PBI-AR global score or subscales were found between men and women, poly- and monoallergic patients, or patients with severe versus mild rhinoconjunctivitis. Patients with asthma reported relevant but lower benefit than patients without asthma. CONCLUSION: After 1 year of birch pollen SLIT treatment, patients reported considerable benefit, mainly due to a reduction of physical symptoms and treatment burden.


Subject(s)
Betula/adverse effects , Plant Extracts/immunology , Plant Extracts/therapeutic use , Pollen/adverse effects , Pollen/immunology , Rhinitis, Allergic, Seasonal/drug therapy , Rhinitis, Allergic, Seasonal/immunology , Adolescent , Adult , Aged , Betula/immunology , Female , Germany/epidemiology , Humans , Male , Middle Aged , Prospective Studies , Sublingual Immunotherapy/methods , Treatment Outcome , Young Adult
3.
Drugs Real World Outcomes ; 4(2): 109-117, 2017 Jun.
Article in English | MEDLINE | ID: mdl-28540507

ABSTRACT

BACKGROUND: Sublingual immunotherapy (SLIT) is a safe/well-tolerated alternative to allergen injection immunotherapy for allergic rhinoconjunctivitis (ARC). Patient adherence is essential and patient-related outcome measures including treatment satisfaction are informative/indicative of adherence. OBJECTIVE: The aim was to assess treatment satisfaction with five-grass pollen tablet SLIT under real-life conditions. METHODS: Treatment satisfaction among adults taking SLIT with a five-grass pollen tablet for grass pollen-related ARC was assessed with QUARTIS, a self-report questionnaire dedicated to the management of patients treated with SLIT for ARC. This 1-year prospective, non-interventional, post-authorization study was conducted in Germany between 2008 and 2010. RESULTS: Of the 327 patients treated with the five-grass pollen tablet, 253 completed the QUARTIS questionnaire before and during (at least one item) treatment and were included in this analysis. Between the baseline and the treatment season, significant improvements were documented in nasal and ocular symptoms, and in the impact of allergy on everyday life. At the end of the first treatment period, patients had an improved opinion of the ease of SLIT intake and a significantly improved perception of SLIT. Compliance, overall satisfaction and motivation to continue SLIT the following year were good. Physicians' assessments showed reduced symptoms and a reduced need for symptomatic medication throughout the study. SLIT was also well tolerated. CONCLUSION: Under real-life conditions, five-grass pollen tablet treatment was associated with a good level of treatment satisfaction, good symptom control, a reduced need for symptomatic medication, and favourable tolerability. These facets impacted favourably on patient functioning, disposition towards this medication, and adherence.

4.
Adv Ther ; 34(6): 1382-1397, 2017 06.
Article in English | MEDLINE | ID: mdl-28455783

ABSTRACT

INTRODUCTION: Allergen immunotherapy is the only treatment option for allergic rhinitis with disease-altering potential. It was the objective of this study to assess the effectiveness and tolerability of a 5-grass pollen tablet in a large population of non-selected grass pollen allergic patients, i.e. patients with different clinical profiles in daily clinical practice. METHODS: In a 2-year, prospective, open-label, multicenter, non-controlled, observational study patients were included from 327 centers across Germany. Rhinoconjunctivitis symptoms, symptomatic medication intake and adverse events were recorded. RESULTS: A total of 1482 patients aged 4-75 years were included. During the 2-year period of 5-grass pollen tablet therapy, mean rhinoconjunctivitis score decreased significantly in the overall study population by 65.5% (P < 0.001). The percentage of patients taking symptomatic medication decreased from 83.8% to 42.7%. Mean 2-year improvements in rhinoconjunctivitis scores and decreases in the percentage of patients taking symptomatic medication were broadly similar in adults, adolescents and children, in patients with polyallergy versus monoallergy, and in patients with/without asthma. Among polyallergic patients, concomitant application of another specific immunotherapy did not impair treatment outcomes. Adverse drug reactions, predominantly affecting the local application area, occurred in 15.4% of the overall patient population (n = 229). No cases of anaphylaxis or epinephrine use were documented. CONCLUSION: This study indicates that sublingual immunotherapy with the 5-grass pollen tablet is well tolerated and provides sustained effectiveness over 2 years in patients with different clinical profiles, producing a significant decrease in allergic symptoms and a reduction in the use of symptomatic medication. FUNDING: Stallergenes GmbH.


Subject(s)
Poaceae , Pollen , Rhinitis, Allergic, Seasonal/drug therapy , Sublingual Immunotherapy/methods , Administration, Sublingual , Adolescent , Adult , Aged , Child , Child, Preschool , Conjunctivitis, Allergic/drug therapy , Female , Germany , Humans , Male , Middle Aged , Prospective Studies , Rhinitis, Allergic/drug therapy , Treatment Outcome , Young Adult
5.
Curr Med Res Opin ; 31(12): 2249-59, 2015 Dec.
Article in English | MEDLINE | ID: mdl-26366617

ABSTRACT

OBJECTIVES: To document the effectiveness and safety of sublingual allergen immunotherapy (SLIT) with a five-grass pollen tablet (Oralair ) and compare different treatment options in a broad, non-selected population of patients in a real-world clinical setting. RESEARCH DESIGN AND METHODS: This was a 2 year, open, prospective, multicenter, single-arm, non-interventional study. Patients with a history of clinically relevant allergic symptoms caused by grass pollen, confirmed by skin prick testing, received treatment with the five-grass pollen tablet. Concomitant treatment with symptomatic medication and/or additional SLIT or subcutaneous immunotherapy (SCIT) was permitted. Twelve-month data are presented here. Effectiveness was assessed comparing a combined rhinoconjunctivitis (RC) score derived from the severity of rhinitis and conjunctivitis symptoms under treatment with retrospective data of the previous year. RESULTS: A total of 1408 patients participated in the study, of whom 434 were children/adolescents and 962 polyallergic. Compared with the grass pollen season preceding five-grass pollen tablet treatment, a statistically significant reduction of 49.9% was achieved in RC score for the total population (p < 0.001), and an improvement in overall health was perceived by 90.9% of patients. The overall population of polyallergic patients derived similar benefits from treatment with the five-grass pollen tablet as monoallergic patients. The percentage reduction in RC score was larger in polyallergic patients taking no additional therapy (60.2%) than in those taking concomitant symptomatic medication (38.1%) or allergen immunotherapy (AIT) (50.8%). Within the last of these groups, RC score improved by 47.6% among patients receiving additional SCIT, versus 54.8% with additional SLIT. Adverse drug reactions, reported in 15.3% of study participants, were mostly local in nature and mild or moderate in intensity. CONCLUSIONS: After 1 year of treatment, polyallergic patients responded similarly to the five-grass pollen tablet as monoallergic patients. For polyallergic patients in whom additional treatment was needed, a second SLIT may be more beneficial than a SCIT or symptomatic co-medication.


Subject(s)
Rhinitis, Allergic, Seasonal/therapy , Sublingual Immunotherapy/methods , Adolescent , Adult , Aged , Allergens/immunology , Child , Child, Preschool , Conjunctivitis, Allergic/therapy , Female , Humans , Male , Middle Aged , Poaceae/immunology , Pollen/immunology , Prospective Studies , Retrospective Studies , Seasons , Sublingual Immunotherapy/adverse effects , Tablets/administration & dosage , Young Adult
6.
Biomed Res Int ; 2015: 584291, 2015.
Article in English | MEDLINE | ID: mdl-26351635

ABSTRACT

BACKGROUND: Although the safety and efficacy of sublingual immunotherapy (SLIT) with a five-grass pollen tablet have been demonstrated in randomized clinical trials (RCTs), these outcomes must always be evaluated in real-life medical practice. METHODS: In a prospective, open-label, noninterventional, "real-life" study in Germany, we evaluated the safety, tolerability, and effectiveness of SLIT with a five-grass pollen tablet in adults with grass-pollen-induced allergic rhinoconjunctivitis. RESULTS: 808 adults were enrolled between September 2008 and December 2009. 35.3% of the participants experienced at least one adverse drug reaction (ADR), the most common of which were mild-to-moderate gastrointestinal and respiratory disorders. Serious ADRs considered causally related to SLIT treatment occurred in four patients. Overall, the five-grass pollen tablet was considered to have good or very good tolerability by most investigators and patients. Treatment was associated with the relief of nasal, ocular, and bronchial symptoms and decreased symptomatic medication use. However, interpretation of clinical improvements was limited by lower atmospheric grass pollen levels during the study season (relative to the preceding season). CONCLUSIONS: In a large population of patients treated in real-life medical practice, SLIT with a five-grass pollen tablet was safe and well tolerated. The patient-reported symptom relief suggests that SLIT was associated with clinical benefits.


Subject(s)
Allergens/immunology , Poaceae/immunology , Pollen/immunology , Rhinitis, Allergic, Seasonal/immunology , Tablets/administration & dosage , Administration, Sublingual , Adolescent , Adult , Aged , Aged, 80 and over , Conjunctivitis, Allergic/immunology , Desensitization, Immunologic/methods , Female , Germany , Humans , Male , Middle Aged , Prospective Studies , Seasons , Sublingual Immunotherapy/methods , Young Adult
7.
Pediatr Allergy Immunol ; 25(8): 760-6, 2014 Dec.
Article in English | MEDLINE | ID: mdl-25378225

ABSTRACT

BACKGROUND: The safety and efficacy of pre- and coseasonal sublingual allergen immunotherapy (SLIT) with a 5-grass pollen sublingual tablet have been demonstrated in a randomized clinical trial (RCT) in children and adolescents. Observational, 'real-life' studies can usefully complement the results of RCTs. METHODS: A prospective, open-label, observational, multicentre post-marketing study of children and adolescents (aged 5-17, with grass pollen-induced allergic rhinitis) treated with the 5-grass pollen sublingual tablet was performed between June 2009 and January 2011 in Germany. Adverse events (AEs) were recorded during consultations with the investigating physicians; AEs judged to have at least a possible causal link to the tablet were classified as adverse drug reactions (ADRs). RESULTS: Eight hundred and forty-nine patients were enrolled (by 207 investigating physicians), 829 (mean ± s.d. age: 10.9 ± 3.3 yr) completed the study without major protocol deviations, and 796 were fully documented with respect to AEs. Ninety-four of the 796 patients (11.8%) experienced at least one ADR on the first day of SLIT and 218 (27.4%) experienced at least one ADR during the study. Four hundred and sixty-six of the 596 ADRs (78.2%) were mild or moderate. The most common ADRs were throat irritation (19.1% of the reactions), oral paresthesia (8.2%), oral pruritus (6.5%) and oedema mouth (6.2%). Serious ADRs occurred in five patients. No epinephrine use was reported. Seventy-six of the 829 patients (9.2%) discontinued SLIT due to AEs. Tolerability was judged to be good or very good by patients (84.7%), parents (87.0%) and investigators (89.7%). CONCLUSIONS: In clinical practice, pre- and coseasonal treatment with a 5-grass pollen sublingual tablet is safe and well tolerated in children and adolescents.


Subject(s)
Allergens/immunology , Desensitization, Immunologic/methods , Pollen/immunology , Rhinitis, Allergic/therapy , Tablets/administration & dosage , Administration, Sublingual , Adolescent , Allergens/adverse effects , Child , Child, Preschool , Desensitization, Immunologic/adverse effects , Edema/etiology , Female , Humans , Male , Paresthesia/etiology , Poaceae , Pollen/adverse effects , Prospective Studies , Pruritus/etiology , Rhinitis, Allergic/immunology , Tablets/adverse effects , Withholding Treatment
8.
J Child Lang ; 31(3): 683-712, 2004 Aug.
Article in English | MEDLINE | ID: mdl-15612395

ABSTRACT

This study examines the production of regular and irregular participle forms of German with high and low frequencies using a speeded production task. 40 children in two age groups (five- to seven-year olds, eleven- to twelve-year olds) and 35 adult native speakers of German listened to stem forms of verbs presented in a sentential context and were asked to produce corresponding participle forms as quickly and accurately as possible. Dependent variables were the subjects' participle-production latencies and error rates. We found contrasts between the production of regular and irregular forms in both children and adults, with respect to the production latencies and types of morphological error. Children overapplied the regular patterns to forms that are irregular in the adult language, but not vice versa. High-frequency irregular participles were produced faster (and amongst the children more accurately) than low-frequency ones, whereas regular participles yielded a reverse frequency effect, i.e. longer production latencies for high-frequency forms than for low-frequency ones, in the two groups of children as well as in one subgroup of adults. We explain these findings from the perspective of dual-mechanism models of inflection arguing that the mental mechanisms and representations for processing morphologically complex words ('words' and 'rules') are the same in children and adults, and that the observed child/adult differences in participle production are due to slower and less accurate lexical access in children than in adults.


Subject(s)
Language , Reaction Time , Speech , Verbal Behavior , Vocabulary , Adult , Child , Child, Preschool , Female , Humans , Male , Speech Production Measurement
SELECTION OF CITATIONS
SEARCH DETAIL
...